Loading...
•
Mar 31, 2024
Akero Q1 2024 Earnings Report
Akero Therapeutics reported first quarter financial results and provided business updates.
Key Takeaways
Akero Therapeutics reported first quarter financial results, highlighting significant advancements in the clinical development of EFX and a strong cash position of over $900 million, expected to fund operations into the second half of 2027.
Reported statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH.
Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll.
SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second quarter of 2024.
Cash, cash equivalents, and short-term marketable securities totaled $903.7 million as of March 31, 2024.
Forward Guidance
Akero believes that its current cash, cash equivalents, and short-term marketable securities will be sufficient to fund its Phase 3 SYNCHRONY Histology and Real-World studies through their respective primary endpoints and Akero’s current operating plan into the second half of 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...